Loading
UroGen Pharma Ltd. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 19 Nov 2021.
UroGen Pharma Ltd.: what insiders have been doing
UroGen Pharma Ltd., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Over the twelve months to 18 October 2026, 26 filings were filed, from 12 insiders.
The flow runs one way only: 7 sales worth €3.2M, from 3 insiders, and no purchase. The largest single trade was a sale of €2.4M by Schoenberg Mark, published on 24 August 2026, equal to 0.14% of the market capitalisation.
Compared with its exchange (5,808 companies, median 19 filings), a count of 26 filings is above the norm. Since 2021, the database holds 3 purchases and 11 sales by insiders of the company. The 10-K for the year ended 31 December 2025 shows 109.8 m USD of revenue and -153.5 m USD of net income.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
83
Thresholds
n/a
Buy Volume
€66,753
3 ops. · all time
Sell Volume
€4M
11 ops. · all time
Who traded when
BuySaleMark Schoenberg6 sales
Chris Degnan1 sale
Jason Drew Smith1 sale
Since the insiders bought
- -36.9%Entry US$12.29 · Close at T+365 US$7.76
- -69.8%Entry US$18.23 · Close at T+365 US$5.51
- -69.8%Entry US$18.23 · Close at T+365 US$5.51
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate UroGen Pharma Ltd. Strong Buy (bullish), based on 8 analysts. Average price target: US$60.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$36.58
Analyst consensus
8 analystsStrong buy
US$48.00Target US$60.00(+64%)US$75.00
Income statement
RevenueUS$109.8M
Gross profitUS$97.3M89% margin
EBITDA-US$135.7M-124% margin
Net income-US$153.5M-51.7% margin
Valuation
PER (forward)14.1x
Beta1.58
Balance sheet & cash
Market capUS$1.8B
Total debtUS$128.3M
Free Cash Flow-US$162.7M
Profitability & ownership
ROA-18.1%
% insiders3.5%
% institutions97.8%
Last declaration on 9 October 2026
Declarations83 total
2,202 shares@ US$40.700.0050% mcap100.0% of flowOrdinary sharesSEC144:0001976408-26-000887
4,483 sharesOrdinary SharesSEC:0001437749-26-032421:0
2,202 shares@ US$36.690.0041% mcap100.0% of flowOrdinary SharesSEC:0001437749-26-032421:1
871 shares@ US$44.090.0019% mcap100.0% of flowOrdinary sharesSEC144:0001976408-26-000811
1,519 shares@ US$44.090.0033% mcap100.0% of flowOrdinary sharesSEC144:0001976408-26-000810
1,667 sharesOrdinary SharesSEC:0001437749-26-029965:0
871 shares@ US$42.920.0018% mcap0.4% of flowOrdinary SharesSEC:0001437749-26-029965:1
3,334 sharesOrdinary SharesSEC:0001437749-26-029963:0
1,519 shares@ US$42.540.0031% mcap59.1% of flowOrdinary SharesSEC:0001437749-26-029963:1
2,000 sharesordinary sharesSEC:0001437749-26-029175:0
60,677 shares@ US$47.050.14% mcap33.9% of flowordinary sharesSEC:0001437749-26-028840:0
60,677 shares@ US$47.66620.14% mcap34.3% of flowCOMMONSEC144:0001000275-26-000100
10,000 shares@ US$40.000.020% mcap4.8% of flowOrdinary SharesSEC:0001437749-26-023290:0
10,000 shares@ US$40.00080.020% mcap4.8% of flowCOMMONSEC144:0001000275-26-000093
10,000 shares@ US$35.01430.015% mcap4.2% of flowCOMMONSEC144:0001000275-26-000079
5,222 shares@ US$26.850.0072% mcap1.7% of flowOrdinary sharesSEC144:0001976408-26-000558
2,000 sharesordinary sharesSEC:0001437749-26-006124:0
5,500 sharesOrdinary SharesSEC:0001437749-26-003778:0
1,844 shares@ US$19.690.4% of flowOrdinary SharesSEC:0001437749-26-003040:0
3,333 sharesOrdinary SharesSEC:0001437749-26-002843:0
2,000 sharesordinary sharesSEC:0001437749-25-036576:0
2,000 sharesordinary sharesSEC:0001437749-25-036565:0
2,000 sharesordinary sharesSEC:0001437749-25-036559:0
2,000 sharesordinary sharesSEC:0001437749-25-036555:0
25 of 83 declarations
About UroGen Pharma Ltd.
UroGen Pharma Ltd. is a U.S.-listed biopharmaceutical company traded on NASDAQ under the ticker URGN in the United States (United States). The company is focused on urology, with a particular emphasis on uro-oncology and other specialty urologic diseases that still have meaningful unmet medical needs. UroGen was founded in 2004 and is headquartered in Princeton, New Jersey, with additional operations in Israel. From an equity-investor perspective, the business is best understood as a specialty biotech rather than a diversified pharmaceutical group. ([investors.urogen.com](https://investors.urogen.com/resources/overview/?utm_source=openai))
UroGen’s core differentiator is its proprietary RTGel® reverse-thermal hydrogel platform. RTGel is designed to enable sustained local delivery of medicines in the urinary tract, helping drugs remain in contact with the target tissue for longer periods. That technology underpins both approved products and future pipeline programs, and it is central to the company’s commercial and scientific identity. UroGen positions RTGel as a way to improve therapeutic profiles of existing drugs and to support non-surgical treatment options in anatomically complex urologic settings. ([urogen.com](https://www.urogen.com/our-portfolio?utm_source=openai))
Read moreShow less
The company’s commercial portfolio currently includes JELMYTO® and ZUSDURI™. JELMYTO is mitomycin for pyelocalyceal solution and is used in low-grade upper tract urothelial cancer. ZUSDURI, mitomycin for intravesical solution, is described by UroGen as the first and only FDA-approved medicine for adults with recurrent, low-grade, intermediate-risk non-muscle invasive bladder cancer. This makes UroGen highly focused on a narrow set of urothelial indications where product differentiation, regulatory exclusivity, and specialist physician adoption can matter more than broad primary-care scale. ([urogen.com](https://www.urogen.com/our-portfolio?utm_source=openai))
In competitive terms, UroGen occupies a niche position in uro-oncology. It is not trying to compete across broad oncology categories; instead, it targets defined urologic segments where alternative treatments may be invasive, cumbersome, or less well suited to localized delivery. The company’s pipeline strategy is built around next-generation mitomycin-based assets such as UGN-103 and UGN-104, which are intended to extend the franchise and support lifecycle management around the RTGel platform. That pipeline strategy is important because it can broaden the commercial runway beyond the current marketed products. ([investors.urogen.com](https://investors.urogen.com/news-releases/news-release-details/urogen-announces-zusduritm-launch-track-and-reports-fourth/?utm_source=openai))
Recent developments have been especially important. In 2025, UroGen reported FDA approval and commercial launch activity for ZUSDURI, marking a major transition from a development-led story toward a more commercial one. The company also continued to publish clinical and durability data supporting its lead programs, while management highlighted 2026 as a pivotal year for the launch trajectory. For investors, the key themes are execution, reimbursement, uptake by urology practices, and the company’s ability to convert its regulatory milestones into durable revenue growth. ([investors.urogen.com](https://investors.urogen.com/news-releases/news-release-details/urogen-announces-zusduritm-launch-track-and-reports-fourth?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
